CTLA4 and neoplasm: These inhibitors enhance the cytotoxicity of immune effector cells by affecting cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed cell death protein 1 (PD-1), and PD-1 ligand (PD-L1), and improving the tumor microenvironment (TME) to resist tumor cell growth [9].